Summary & Overview
HCPCS G9133: Prostate Adenocarcinoma, Hormone-Responsive, Metastatic
HCPCS Level II code G9133 designates a disease-status classification for prostate cancer limited to adenocarcinoma that is hormone-responsive with clinical metastases (M1) at diagnosis, intended for use within a Medicare-approved demonstration project. This code matters nationally as a targeted reporting identifier for clinical status in oncology programs that are evaluating outcomes, utilization, or payment models specific to metastatic, hormone-responsive prostate cancer.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context, the typical service setting, and which payers are relevant to coverage and program participation. The publication summarizes benchmarks and policy-relevant considerations tied to demonstration projects, clarifies the code's role in clinical documentation and tracking, and outlines implications for oncology service lines and hospital outpatient departments.
The content provides clinical context for coders and administrators, explains where the code is most likely used, and notes gaps where input data is not available (for example, associated taxonomies and ICD-10 pairings). This national-level summary is intended to support operational planning, billing workflows, and participation decisions for organizations involved in Medicare demonstration efforts involving metastatic, hormone-responsive prostate adenocarcinoma.
Billing Code Overview
HCPCS Level II code G9133 represents a disease status classification for prostate cancer, limited to adenocarcinoma that is hormone-responsive with clinical metastases or M1 at diagnosis. The code is specified for use in a Medicare-approved demonstration project, indicating a targeted reporting or tracking purpose rather than routine outpatient billing.
Service type: Oncology — disease status classification and reporting
Typical site of service: Oncology clinic, hospital outpatient department, or other settings participating in a Medicare demonstration project
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related codes.
Clinical & Coding Specifications
Clinical Context
A 68-year-old man with a new diagnosis of prostate adenocarcinoma presents to a tertiary oncology clinic participating in a Medicare-approved demonstration project. At diagnosis his tumor is hormone-responsive and clinical staging and imaging demonstrate metastatic disease (M1) with bone lesions and pelvic lymphadenopathy. The oncology team documents disease status, hormone responsiveness, extent of clinical metastases, prior treatments, performance status, and planned systemic therapy. Clinical workflow: initial oncology consultation with history, review of pathology confirming adenocarcinoma, review of staging scans (bone scan, CT or MRI), documentation of hormone receptor status and prior androgen-deprivation therapy (if any), multidisciplinary tumor board review for treatment planning, and periodic disease-status updates during the demonstration project. Typical site of service is an outpatient oncology clinic or hospital-based outpatient department, with possible referral for inpatient evaluation if complications arise. Common encounter elements include focused physical exam, review of imaging and lab results (PSA, testosterone), documentation of metastatic sites (M1a/b/c as applicable), and coding of the Medicare demonstration project-specific HCPCS code G9133 to capture disease-status reporting for prostate adenocarcinoma that is hormone-responsive with clinical metastases at diagnosis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural service |